Rutgers Cancer Institute of New Jersey: Exploring Treatment Strategies in T-Cell Acute Lymphoblastic Leukemia
May 13, 2020
May 13, 2020
NEW BRUNSWICK, New Jersey, May 13 -- Rutgers Cancer Institute of New Jersey issued the following news:
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of . . .
Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of . . .